Gilead Sciences, Inc. (NASDAQ:GILD) received a $96.00 target price from investment analysts at Berenberg Bank in a report issued on Thursday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Berenberg Bank’s price target would suggest a potential upside of 18.21% from the company’s previous close.

Other equities analysts have also issued research reports about the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a research report on Monday, August 28th. Vetr raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $89.27 price target for the company in a research report on Wednesday, September 6th. Morgan Stanley reaffirmed an “equal weight” rating and set a $83.00 price target (up previously from $77.00) on shares of Gilead Sciences in a research report on Friday, October 6th. Maxim Group reaffirmed a “hold” rating on shares of Gilead Sciences in a research report on Thursday, July 27th. Finally, ValuEngine lowered shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, September 13th. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $85.64.

Shares of Gilead Sciences (GILD) traded down 0.47% during mid-day trading on Thursday, hitting $81.21. 9,188,325 shares of the stock were exchanged. The company has a 50-day moving average of $82.63 and a 200 day moving average of $72.65. Gilead Sciences has a one year low of $63.76 and a one year high of $86.27. The stock has a market cap of $106.05 billion, a PE ratio of 8.82 and a beta of 1.14.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, beating analysts’ consensus estimates of $2.11 by $0.45. The business had revenue of $7.14 billion during the quarter, compared to analyst estimates of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The company’s revenue was down 8.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $3.08 earnings per share. On average, equities analysts predict that Gilead Sciences will post $8.74 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Berenberg Bank Analysts Give Gilead Sciences, Inc. (GILD) a $96.00 Price Target” was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international copyright law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/22/berenberg-bank-analysts-give-gilead-sciences-inc-gild-a-96-00-price-target.html.

In related news, CFO Robin L. Washington sold 51,820 shares of the firm’s stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $85.00, for a total transaction of $4,404,700.00. Following the transaction, the chief financial officer now owns 43,352 shares of the company’s stock, valued at $3,684,920. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Gregg H. Alton sold 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 1st. The shares were sold at an average price of $75.88, for a total transaction of $1,138,200.00. Following the transaction, the executive vice president now directly owns 106,113 shares in the company, valued at approximately $8,051,854.44. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 446,819 shares of company stock worth $36,338,919. Insiders own 1.30% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of GILD. Keel Point LLC raised its position in shares of Gilead Sciences by 0.4% in the first quarter. Keel Point LLC now owns 3,111 shares of the biopharmaceutical company’s stock valued at $211,000 after purchasing an additional 11 shares during the period. Paradigm Financial Advisors LLC raised its position in shares of Gilead Sciences by 0.3% in the second quarter. Paradigm Financial Advisors LLC now owns 8,723 shares of the biopharmaceutical company’s stock valued at $617,000 after purchasing an additional 26 shares during the period. West Oak Capital LLC raised its position in shares of Gilead Sciences by 0.7% in the second quarter. West Oak Capital LLC now owns 4,666 shares of the biopharmaceutical company’s stock valued at $330,000 after purchasing an additional 32 shares during the period. First Heartland Consultants Inc. raised its position in shares of Gilead Sciences by 0.4% in the second quarter. First Heartland Consultants Inc. now owns 8,927 shares of the biopharmaceutical company’s stock valued at $632,000 after purchasing an additional 39 shares during the period. Finally, Princeton Portfolio Strategies Group LLC raised its position in shares of Gilead Sciences by 0.4% in the second quarter. Princeton Portfolio Strategies Group LLC now owns 9,766 shares of the biopharmaceutical company’s stock valued at $691,000 after purchasing an additional 41 shares during the period. 73.97% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.